Company profile for Earendil Labs

NEW Drugs in Dev.: 2
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Earendil Labs is a US-based biotech company redefining biopharmaceutical innovation with its cutting-edge AI-powered platform. By combining advanced machine learning, generative protein engineering, and high-throughput experimental techniques, Earendil Labs and its affiliate Helixon Therapeutics streamline drug discovery & research process with aim of significantly accelerating drug development. Earendil Labs' proprietary inte...
Earendil Labs is a US-based biotech company redefining biopharmaceutical innovation with its cutting-edge AI-powered platform. By combining advanced machine learning, generative protein engineering, and high-throughput experimental techniques, Earendil Labs and its affiliate Helixon Therapeutics streamline drug discovery & research process with aim of significantly accelerating drug development. Earendil Labs' proprietary integrated framework enables precise optimization of functionality, manufacturability, and developability of protein-based biologics with first-in-class or best-in-class potential.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Middletown, Delaware
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/earendil-labs-announces-strategic-collaboration-with-sanofi-to-discover-bispecific-antibodies-for-autoimmune-diseases-302652305.html

PR NEWSWIRE
06 Jan 2026

https://www.prnewswire.com/news-releases/earendil-labs-announces-initiation-of-a-phase-1-study-of-a-half-life-extended-novel-anti-tl1a-antibody-302502297.html

PR NEWSWIRE
11 Jul 2025

https://www.fiercebiotech.com/biotech/sanofi-pens-18b-deal-2-bispecific-antibodies-aimed-autoimmune-immunology

FIERCE BIOTECH
17 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty